Melinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017

Presentations includes Baxdela activity in obese and other challenging patient types, as well as a presentation on activity of pyrrolocytosine family against MCR-1 MDR bacteria

Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that there will be nine presentations on Melinta programs at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which is being held April 22-25, 2017 in Vienna, Austria. These presentations include six posters and e-posters describing the clinical experience with Baxdela™ (delafloxacin), an investigational anionic fluoroquinolone, including important insights into the treatment of challenging patient types such as those who have diabetes, renal impairment or obesity.